Research and clinical support for the PreDx® DRS

This study used ultra-sensitive Molecular Counting Technology to identify the serum biomarkers that best indicate a high risk for developing type 2 diabetes. Starting with baseline blood samples from a large population of healthy subjects, 89 markers were identified. Over a five-year period, 6% of subjects developed diabetes, and from this 6% Tethys narrowed the markers down to less than 20.

Data presented in the publication are based on the Tethys research platform. The paper does not represent the performance characteristics of the PreDx Diabetes Risk Score. For information on performance characteristics of Tethys products, please contact Tethys Bioscience or your Tethys representative.

In short, the purpose of this study, conducted in the Tethys Bioscience Clinical Lab, was to develop a model for assessing the risk of developing type 2 diabetes within a five-year time period using a panel of 64 circulating biomarkers. The study demonstrates that the PreDx Diabetes Risk Score is better at risk prediction than impaired fasting glucose or metabolic syndrome.

This study demonstrates the validity of the research model that formed the basis for the development of the DRS. Findings conclude that multiple biomarkers are superior to single-risk indicators or clinical models at estimating five-year risk of progression to type 2 diabetes.

Data presented in the publication are based on the Tethys research platform. The paper does not represent the performance characteristics of the PreDx Diabetes Risk Score. For information on performance characteristics of Tethys products, please contact Tethys Bioscience or your Tethys representative.

This multicenter, epidemiological study was used to further evaluate the performance of the PreDx DRS by examining insulin resistance and cardiovascular risk factors and disease across different ethnic groups and varying states of glucose tolerance. A variety of subpopulations of the IRAS cohort, defined by race/ethnicity and gender, were also examined. Conclusions reveal no significant difference in performance across the different ethnic subpopulations or genders in the IRAS study population.*

* Because HbA1c values at baseline were not available, data from NHANES surveys were used to estimate an appropriate mean HbA1c of 5.4% for use in the model.